62 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
7 May 24
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
7:39am
:
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
are a part.
Company Overview
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule … biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative
424B5
ppcxu
11 Mar 24
Prospectus supplement for primary offering
4:06pm
424B4
727t47er 7hzb66qnb
8 Jan 24
Prospectus supplement with pricing info
4:11pm
8-K
EX-99.1
vedf6gkjotjfsz7jiit2
4 Jan 24
Other Events
4:21pm
8-K
EX-99.1
a4r at499btl23vt
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
vi9 an815hr
12 Sep 23
Other Events
7:00am
8-K
EX-99.1
csmpy8l2n
24 Aug 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
k2d9lb r7xwv
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
sva 6k2ce
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.1
bflgp z73mvmw58pp21
4 May 23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
S-3
wv9u7wrz
23 Dec 22
Shelf registration
4:16pm